ALDX
Another lawsuit, because biotech wasn’t spicy enough
Aldeyra Therapeutics is now dealing with a class action lawsuit, according to Pomerantz LLP. The suit is tied to the company’s March 17 disclosure that the FDA sent a Complete Response Letter for reproxalap, its dry-eye drug candidate.
Why investors should care
This is the kind of news that can keep a stock in the penalty box. When a biotech gets an FDA no-thanks letter and then gets dragged into class-action territory, investors usually start asking two questions: how bad is the underlying drug issue, and how much more pain is coming from the legal side?
The real-world impact
The article is basically a heads-up for shareholders who think they may have losses and want to join the case. That doesn’t automatically mean Aldeyra is headed for disaster, but it does mean the overhang is still hanging around like a houseguest who won’t take the hint.
Big picture: for ALDX holders, this is less about surprise and more about confirmation that the reproxalap saga now has a legal chapter too.